Background Bisphosphonates form part of standard therapy for hypercalcemia and the
prevention of skeletal events in some cancers. However, the role of bisphosphonates in pain …

Background: Bisphosphonates and denosumab are well-established therapies to reduce the
frequency and severity of skeletal-related events in patients with bone metastasis. However …

AIM: To evaluate the evidence for denosumab for the treatment of bone metastases
secondary to solid tumours and, using a network meta-analysis, indirectly compare …

The aim of this review was to evaluate the methods of pain measurement in controlled
clinical trials in oncology published between 1999 and 2002. An electronic literature search …

Systematic review of the clinical effectiveness and cost-effectiveness, and economic
evaluation, of denosumab for the treatment Page 1 DOI 10.3310/hta17290 HealtH …

Several disorders of increased bone turnover and low bone mineral density (BMD) are
associated with severe pain that is refractory to treatment with conventional and even opioid …

Context The difficulties in defining a palliative care patient accentuate the need to provide
stringent descriptions of the patient population in palliative care research. Objectives To …

The preparation and characterization of a novel polymeric drug‐delivery system designed
for bone targeting of antineoplastics is described. The system was based on biocompatible …

Bone metastases are common in patients with advanced-stage cancer; they can lead to
skeletal complications (ie, pathologic fractures, spinal cord compression, tumor-induced …

Purpose When treating metastatic bone disease, relief of bone pain is often a key outcome.
Because pain cannot be quantified with objective clinical measures, patient-reported …